Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 75 versus HYPAQUE SODIUM 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 75 versus HYPAQUE SODIUM 20.
HYPAQUE-M,75% vs HYPAQUE SODIUM 20%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast due to high iodine content. It increases the density of vascular structures and tissues, allowing visualization of anatomical structures during imaging procedures.
Hypaque sodium is an ionic monomeric iodinated contrast medium that absorbs X-rays due to its iodine content, providing radiographic contrast. It increases the density of vascular structures and organ parenchyma, allowing visualization during imaging procedures.
1.2-1.5 mL/kg IV as a single dose for CT enhancement; maximum 150 mL per procedure.
Intravenous: 30-60 mL (6-12 g iodine) administered as a bolus or infusion for excretory urography; may be repeated up to a total of 125 mL (25 g iodine). Intra-arterial: Variable based on procedure, typically 8-30 mL for selective angiography.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria).
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment.
Renal excretion: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Renal: >95% unchanged via glomerular filtration within 24 hours; <5% biliary/fecal.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent